H49R MUTATION OF THE SOD1 GENE AS A CAUSE OF PROGRESSIVE MUSCULAR ATROPHY: A CLINICAL CASE

Amyotrophic lateral sclerosis (ALS) is a severe neurodegenerative disease within the spectrum of motor neuron disorders, selectively targeting central and peripheral motor neurons in the brain and spinal cord, with highly variable clinical manifestations. One rare form of ALS is progressive muscular atrophy (PMA), primarily characterized by the selective involvement of peripheral motor neurons and a slower, less aggressive progression compared to classical ALS. Currently, the scientific community lacks consensus on whether PMA should be classified as a distinct nosological entity or as a subtype of ALS.

Recent advancements in genetic research have identified that familial and hereditary forms of ALS are most frequently linked to mutations in the SOD1, TARDBP, C9orf72, and FUS genes, among others. Moreover, increasing progress in genetic testing now enables the identification of mutant genes responsible for various phenotypes. Understanding the genetic underpinnings of motor neuron diseases is crucial for elucidating their pathogenesis, which may pave the way for the development of novel diagnostic and therapeutic strategies.

This article presents a clinical case involving a patient with a PMA phenotype associated with the H49R mutation in the SOD1 gene. A comprehensive account of the patient’s anamnesis, clinical presentation, molecular-genetic findings, as well as results from instrumental investigations, including electromyography and magnetic resonance imaging, is provided. The article discusses the potential nosological autonomy of PMA and its association with the H49R mutation, referencing current data from both Russian and international studies. Additionally, the article highlights the challenges of differential diagnosis, particularly in distinguishing PMA from other neurodegenerative diseases with similar clinical profiles.

This case contributes to the expanding knowledge of the heterogeneity of motor neuron diseases and underscores the importance of molecular-genetic testing in predicting disease prognosis and guiding patient management.

1. Zakharova M, Brylev L, Avdonina I, et al. Amyotrophic lateral sclerosis. In: Gusev E, Konovalov A, Skvortsova V. (eds.) Neurology: National Guidelines: in 2 volumes. Vol. 1. Moscow: GEOTAR-Media, 2019: 644– 646. (in Russian)

2. Bakulin IS, Zakroyshchikova IV, Suponeva NA, Zakharova MN Amyotrophic lateral sclerosis: clinical heterogeneity and approaches to classification. Neuromuscular diseases. 2017; 7(3): 10–20. DOI: 10.17650/2222-8721-2017-7-3-10-20. (in Russian)

3. Vasiliev AV, Eliseeva AV, Ivanova MV, et al. Methods for diagnostics and correction of respiratory disorders in amyotrophic lateral sclerosis. Annals of Clinical and Experimental Neurology, 2018; 12(4): 76–85. (in Russian)

4. Xu L, Liu T, Liu L, et al. Global variation in prevalence and incidence of amyotrophic lateral sclerosis: a systematic review and meta-analysis. Journal of Neurology. 2020; 267 (4): 944–953. DOI: 10.1007/s00415-019-09652-y.

5. Brylev L, Ataulina A, Fominykh V et al. The epidemiology of amyotrophic lateral sclerosis in Moscow (Russia). Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 2020; 21(5-6): 410-415. DOI: 10.1080/21678421.2020.1752252.

6. Samoshkina OI. Clinical and epidemiological features of amyotrophic lateral sclerosis in St. Petersburg and the Leningrad Region. Summary of Candidate’s dissertation (Nervous diseases). St. Petersburg, 2007. (in Russian)

7. Pervushina EV, Bakhtiyarova KZ. Clinical characteristics of amyotrophic lateral sclerosis in the Republic of Bashkortostan. Practical Medicine. 2015; 5(90): 108–110. (in Russian)

8. Ermilov EA, Isaeva NV. Epidemiology of amyotrophic lateral sclerosis in Krasnoyarsk Krai. Neuromuscular Diseases. 2023; 13(4): 20–29. DOI: 10.17650/2222-8721-2023-13-4-20-29.

9. Davydova TK. Clinical and epidemiological characteristics of amyotrophic lateral sclerosis in the Republic of Sakha (Yakutia). Summary of Candidate’s dissertation (Nerve Diseases). Irkutsk, 2010. (in Russian)

10. Berdyński M, Miszta P, Safranow K, et al. SOD1 mutations associated with amyotrophic lateral sclerosis analysis of variant severity. Scientific Reports. 2022; 12 (1): 103. DOI: 10.1038/s41598-021-03891-8.

11. Xu L, Chen L, Fan D, et al. Calculation of the prevalence of progressive muscular atrophy among adults in China based on urban medical insurance data from 15 provinces. Journal of Beijing University (Health science). 2020; 52(3): 521–526. DOI: 10.19723/j.issn.1671-167X.2020.03.019.

12. Barceló M, Franquet A, Solans M, et al. Estimation of the prevalence and incidence of motor neuron diseases in two Spanish regions: Catalonia and Valencia. Scientific Reports. 2021; 11(1). DOI: 10.1038/s41598-021-85395-z.

13. Liewluck T, Saperstein D. Progressive Muscular Atrophy. Neurologic Clinics. 2015; 33(4): 761–773. DOI: 10.1016/j.ncl.2015.07.005.

14. Huang М, Liu U, Yao X, et al. Variability in SOD1-associated amyotrophic lateral sclerosis: geographic patterns, clinical heterogeneity, molecular alterations, and therapeutic implications. Translational Neurodegeneration. 2024; 13(1): 28. DOI: 10.1186/s40035-024-00416-x.

15. Peggion C, Scalcon V, Nies K, et al. SOD1 in ALS: Taking Stock in Pathogenic Mechanisms and the Role of Glial and Muscle Cells. Antioxidants. 2022; 11(4). DOI 10.3390/antiox11040614.

16. Chestkov IV, Vasilyeva EA, Illarioshkin SN, et al. A system for studying amyotrophic lateral sclerosis based on patient-specific induced pluripotent stem cells. Acta Naturae. 2014; 6; 1(20): 58-65. (in Russian)

17. Shpilyukova YuA, Illarioshkin SN. Spinal muscular atrophy in adults: problems of early diagnosis. Neuromuscular diseases. 2022; 12(4): 37-45. DOI: 10.17650/2222-8721-2022-12-4-37-45. (in Russian)

18. Pinto W, Souza P, Badia B, et al. Adult-onset non-5q proximal spinal muscular atrophy: a comprehensive review. Arquivos de Neuro-Psiquiatria. 2021; 79(10): 912-923. DOI 10.1590/0004-282X-ANP-2020-0429.

19. Shchagina OA, Mironovich OL, Zabnenkova VV, et al. Expansion of the CAG repeat in exon 1 of the AR gene in patients with spinal amyotrophy. Medical Genetics. 2017; 16(9): 31-36. (in Russian)

20. Pinto W, Debona R, Nunes P, et al. Atypical motor neuron disease variants: still a diagnostic challenge in neurology. Revue Neurologique (Paris). 2019; 175(4): 221-232. DOI: 10.1016/j.neurol.2018.04.016.

21. Saberi S, Stauffer J, Schulte D, Ravits J. Neuropathology of Amyotrophic Lateral Sclerosis and its variants. Neurologic Clinics. 2015; 33(4): 855-876. DOI: 10.1016/j.ncl.2015.07.012.

22. Riku Y, Atsuta N, Yoshida M, et al. Differential motor neuron involvement in progressive muscular atrophy: a comparative study with amyotrophic lateral sclerosis. BMJ Open. 2014; 4(5): e005213. DOI: 10.1136/bmjopen-2014-005213.

23. Zou Z, Liu M, Li ., Cui L. H46R SOD1 mutation is consistently associated with a relatively benign form of amyotrophic lateral sclerosis with slow progression. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 2016; 17(7-8): 610-613. DOI 10.1080/21678421.2016.1199698.